Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Efavirenz & Truvada (COMET Study): Phase 4 Evaluation of Switching Twice Daily Combivir to Once-Daily Regimen Co-Formulated Truvada in Virologically Suppressed HIV Infected Patients Taking Efavirenz.

NCT00224458 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00224458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00224458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Efavirenz & Truvada (COMET Study): Phase 4 Evaluation of Switching Twice Daily Combivir to Once-Daily Regimen Co-Formulated Truvada in Virologically Suppressed HIV Infected Patients Taking Efavirenz.
Lead sponsor
Gilead Sciences
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2004
Completion date
February 28, 2006
Enrollment
400
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections